Neurogenesis, Inc.

NEUN · Other OTC · USD

0,0001USD

0,00 (0,00 %)Stand 9. Nov., 21:00

Vortag 0,0001

Kennzahlen

Eröffnung
0,0001
Vortag
0,0001
Tagesspanne
0,0001 – 0,0001
52 Wochen
0,0001 – 0,0001
Volumen
75.701
Ø Volumen
69.952
Börsenwert
8226 $
KGV
0,5
Gewinn je Aktie (TTM)
–
Dividendenrendite
0,0 %
Beta
6,4
Nächste Zahlen
–

Finanzen

USDFY 2013FY 2012FY 2011
Umsatz399.157471.308563.358
Herstellungskosten107.734216.073221.487
Bruttogewinn291.422255.235341.870
Forschung und Entwicklung000
Vertrieb und Verwaltung258.147262.288371.490
Operatives Ergebnis32.860−7939−29.941
EBITDA35.810−6963−29.438
Nettogewinn15.611−32.645−57.223
Gewinn je Aktie (verwässert)0,00-0,00-0,00

Bewertung

Letzte 12 Monate

KGV
0,5
Kurs-Umsatz-Verhältnis
0,0
Kurs-Buchwert-Verhältnis
-0,1
PEG
0,0
Bruttomarge
73,0 %
Operative Marge
8,2 %
Nettomarge
3,9 %
Verschuldungsgrad
-1,4
EV/EBITDA
3,9
Eigenkapitalrendite
−12,0 %
Kapitalrendite (ROIC)
78,7 %
Free-Cashflow-Rendite
−195,4 %
FY 2013FY 2012FY 2011
Bruttomarge73,0 %54,2 %60,7 %
Operative Marge8,2 %−1,7 %−5,3 %
Nettomarge3,9 %−6,9 %−10,2 %
KGV17,0-30,0-3,8
Kurs-Umsatz-Verhältnis0,72,10,4
Kurs-Buchwert-Verhältnis-2,6-6,4-1,8
Verschuldungsgrad-1,4-1,0-1,2
Liquidität 3. Grades0,90,60,7
Dividendenrendite0,0 %0,0 %0,0 %
Unternehmenswert412.863,261,14 Mio.359.843,95
EV/EBITDA11,5-164,4-12,2
Eigenkapitalrendite−14,8 %21,2 %47,1 %
Kapitalrendite (ROIC)78,7 %−82,9 %−131,0 %
Free-Cashflow-Rendite−5,7 %0,1 %2,9 %

Wachstum

FY 2013FY 2012FY 2011
Umsatz−15,3 %−16,3 %0,0 %
Bruttogewinn+14,2 %−25,3 %0,0 %
Operatives Ergebnis+513,9 %+73,5 %0,0 %
Nettogewinn+147,8 %+43,0 %0,0 %
Gewinn je Aktie+140,0 %+44,4 %0,0 %
Freier Cashflow−1.534,8 %−82,4 %0,0 %
Dividende je Aktie0,0 %0,0 %0,0 %

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Quartalszahlen

Gewinn je Aktie · Erwartet
Gewinn je Aktie · Tatsächlich
Abweichung
Umsatz · Tatsächlich

Dividenden und Splits

Keine Dividenden gezahlt.

Aktiensplits

  • 29. Juni 200525:1

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

–

Vergleichbare Unternehmen

Über das Unternehmen

Neurogenesis, Inc. manufactures and sells nutritional supplements primarily in the United States. The company offers NeuBecalm’d, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm'd Chewables that reduces the effects of stress and enhance focus; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long-term use of alcohol. It also provides NeuReplenish, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of chemical stimulants; NeuRelieve, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of antianxiety drugs, and to be used in conjunction with professional support during the tapering process; and NeuSlim, which aids in the reduction of cravings (or urges) for simple carbohydrates, to reduce excessive appetite in general, and to assist in healthy moderation of nutritional needs. In addition, the company offers NeuBecalm'd/NeuRelieve Combo, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the prolonged use of prescription pain pills or from the use of opiate drugs, such as heroin or methadone, as well as used in conjunction with professional support during the tapering process. Neurogenesis, Inc. has a research collaboration with the University of Edinburgh for the development of various platform approaches to enable gene therapies. The company was founded in 1984 and is headquartered in League City, Texas.

Führung

  • Albert H. BieserChairman & President
  • Dimitrios KarussisCo-Founder & Chief Scientific Officer
  • Ibrahim KassisCo-Founder & Chief Technology Officer
  • Mark S. Freedman CSPQ FAAN FRCPCChief Medical & Head of Scientific Advisory Board
  • Nir NetzerChief Operating Officer
  • Tal GilatCo-Founder & Chief Executive Officer
CEO
Tal Gilat
Mitarbeitende
307
Hauptsitz
League City, TX, US
Sektor
Healthcare
Branche
Medical - Pharmaceuticals
Börsengang
5. Juni 1998

Nachrichten

Gerade keine Nachrichten zu diesem Unternehmen.

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.